Phase II Trial of Pulsed Radiotherapy Combined With Tislelizumab in Patients With Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma
Overview
- Phase
- Phase 2
- Intervention
- Tislelizumab
- Conditions
- Head and Neck Cancer
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Enrollment
- 20
- Locations
- 2
- Primary Endpoint
- Objective response rate (ORR) using iRECIST 1.1 criteria
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
The purpose of this study is to determine the efficacy and safety of pulsed radiotherapy given concomitantly with Tislelizumab and as maintenance therapy in participants with locoregionally recurrent head and neck squamous cell carcinoma ( HNSCC).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Confirmed squamous cell head and neck cancer, A karnofsky performance status≥
- •Previous radical therapy (surgery ± chemoradiotherapy or radical chemoradiotherapy) and the records of radiation fields and dosage of previous treatment can be obtained.
- •Inoperable or completely resectable under MDT consultation.
- •Has evaluable tumor burden (measurable and/or non-measurable tumor lesions) assessed by computed tomography scan or magnetic resonance imaging, based on RECIST version 1.1
- •Female participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study therapy
- •Female and male participants of reproductive potential must agree to use adequate contraception throughout the study period and for up to 180 days after the last dose of study therapy
Exclusion Criteria
- •Pregnant or breastfeeding, or planning to become pregnant during the study period
- •The patient had another malignant tumor expcet HNSCC
- •Have an active autoimmune disease or immunodeficiency, including but not limited to myasthenia gravis, interstitial pneumonia, enteritis, autoimmune hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, test positive for HIV or have a history of any of these diseases, or have a history of organ transplantation;
- •They had received reradiotherapy within 1 month prior to entering the study
- •Receiving systemic immunosuppressive drugs within 2 weeks prior to commencing study treatment, or anticipating needing systemic immunosuppressive drugs during study treatment;
- •having received systemic immune-stimulating agents (including but not limited to interferon or interleukin-2 \[IL-2\]) within 4 weeks prior to study treatment initiation or remaining within 5 half-lives (whichever is longer);
- •A history of other malignancies within the past 5 years, except cured cervical carcinoma in situ, non-melanoma skin cancer, localized prostate cancer, and ductal carcinoma in situ;
- •Severe cardiovascular disease (e.g., New York College of Cardiology heart disease class Ⅱ or greater, myocardial infarction, or cerebrovascular accident), unstable arrhythmia, or unstable angina within 3 months before commences study treatment;
- •The subject has an active infection or infectious disease, or develops a fever of unknown origin (body temperature \>38.5 ° C) during screening and before the first dose;
- •had received therapeutic oral or intravenous antibiotics within 2 weeks prior to starting the study; Patients receiving prophylactic antibiotic therapy, such as prevention of urinary tract infection or chronic obstructive pulmonary disease, were enrolled.
Arms & Interventions
Tislelizumab + Pulse radiation
Participants receive pulsed radiationtherapy concurrent with 3 cycles of Tislelizumab followed by an additional 32 cycles of Tislelizumab alone as maintenance therapy.
Intervention: Tislelizumab
Tislelizumab + Pulse radiation
Participants receive pulsed radiationtherapy concurrent with 3 cycles of Tislelizumab followed by an additional 32 cycles of Tislelizumab alone as maintenance therapy.
Intervention: Pulse radiation
Outcomes
Primary Outcomes
Objective response rate (ORR) using iRECIST 1.1 criteria
Time Frame: From time of first dose of study treatment until disease progression or death (up to 2 years)
ORR is defined as the proportion of patients who achieved a best response of complete response (CR) or partial response (PR) using iRECIST 1.1 criteria, and will be evaluated for both the lesion(s) treated with RT, referred to as "Target lesion (RT+ Tisle), as well as the lesion(s) not treated with RT (if applicable), referred to as "Target lesion (Tisle only)", per the prescribed treatment.
Adverse Events (AEs)
Time Frame: From time of first dose of study treatment until the end of follow-up (up to 2 years)
Number of participants experiencing any sign, symptom, disease, or worsening of preexisting condition temporally associated with study therapy and irrespective of causality to study therapy.
Secondary Outcomes
- Duration of Response (DOR)(From time of first dose of study treatment until disease progression or death (up to 2 years))
- Progression Free Survival (PFS)(From time of first dose of study treatment until disease progression or death (up to 2 years))
- Change From Baseline Quality of Life (GHS/QoL)(From time of first dose of study treatment until disease progression or death (up to 2 years))